Kowa Co. Ltd.
- Address
- 3 Chome 6-29 Nishiki, Naka Ku
Sponsor Overview
Specializations
Hypercholesterolemia and lipid-lowering therapy
Kowa Co. Ltd. is engaged in clinical research focused on hypercholesterolemia, with attention to patients who have not achieved sufficient control with existing statin treatment. Its trial activity reflects interest in improving management of elevated low-density lipoprotein cholesterol in cardiovascular risk reduction settings.
- LDL-C control
- Statin inadequate response
- Cardiovascular risk management
The sponsor’s research activity in this area is centered on treatment options for persistent dyslipidemia in adults requiring additional cholesterol management.
Cardiometabolic disease
The clinical focus extends to disorders of lipid metabolism that contribute to broader cardiometabolic health concerns. Research in this field aligns with therapeutic interest in reducing atherogenic lipid burden and supporting long-term prevention of atherosclerotic complications.
- Lipid metabolism disorders
- Atherosclerotic risk
- Cholesterol management
These studies place emphasis on therapeutic strategies for patients whose lipid profiles remain above target despite established treatment.
Safety and tolerability in chronic treatment
Kowa Co. Ltd. also examines the safety profile of therapy in individuals receiving ongoing treatment for elevated LDL cholesterol. This includes monitoring for adverse events and adverse drug reactions in the context of sustained lipid management.
- Adverse events
- Adverse drug reactions
- Long-term tolerability
The sponsor’s interest includes understanding how patients with persistent hyperlipidemia respond to treatment in routine clinical use.
Adult outpatient cardiovascular care
The sponsor’s trial activity is directed toward adult participants managed in outpatient settings for dyslipidemia and related cardiovascular prevention needs. The research setting reflects practical treatment questions relevant to ongoing care in patients with insufficient response to standard therapy.
- Outpatient cardiovascular care
- Dyslipidemia
- Secondary prevention
This area supports clinical interest in optimizing lipid control for patients requiring continued management of elevated cholesterol.
Sponsored Trials
| Trial Name | Country | Status |
|---|---|---|
| Efficacy and Safety of K-924 in Participants with Hypercholesterolemia with Inadequate Response to Pitavastatin 4 mg: A Phase 3, Randomized, Active-Controlled Trial |  Spain | Recruiting |
Data & Insights
This sponsor works with 1 molecule, of which 0 are not being studied by other sponsors.
This sponsor has worked with 5 sites across their trial portfolio.
Therapeutic Focus
- 1.Cardiovascular Diseases1 trial359 other sponsors
Partnered Research Centres
5 centres- Address
- Carrer De La Feixa Llarga S/N, 08907 L'hospitalet De Llobregat
- Address
- Paseo De La Castellana 261, 28046 Madrid
- Address
- Calle De Juan Bravo 49, 28006 Madrid
- Address
- Campus De Teatinos Sn, Puerto De La Torre, 29010 Málaga
- Address
- Poboado Nucleo Rural La Jubias 82, 15006 A Coruna Galicia
Want to get in touch with this sponsor?
Send a question and we'll pass it on to Kowa Co. Ltd..
Need a custom report on this sponsor?
Competitive positioning, market entry, partnership opportunities — tell us the question.
Is something out of date?
Tell us what needs correcting and we'll update this profile.